Posted from: Friday, October 30, 2015 - 11:54 AM - Present

Praxbind Approved to Reverse Anticoagulant Effects of Pradaxa

October 16, 2015 – Boehringer Ingelheim received accelerated U.S. Food and Drug Administration approval for its Praxbind (idarucizumab). Praxbind is indicated to reverse the anticoagulation effects of Pradaxa (dabigatran etexilate mesylate) also manufactured by Boehringer Ingelheim.  Pradaxa is used for emergency surgery or urgent procedures, and in life threatening or uncontrolled bleeding episodes. Praxbind is a humanized monoclonal antibody fragment that is administered as a single intravenous infusion while Pradaxa is an oral direct thrombin inhibitor used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Pradaxa is also used for the treatment and prevention of deep venous thrombosis and pulmonary embolism.

The recommended dose of Praxbind is 5g. Note that Praxbind is the first reversal agent approved specifically for Pradaxa and its continued approval is contingent upon additional clinical data confirming its clinical benefit to be submitted by Boehringer Ingelheim.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Saturday, November 09, 2019 - 10:55 AM.